GSA Capital Partners LLP acquired a new position in shares of MEDNAX Inc (NYSE:MD) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 12,847 shares of the company’s stock, valued at approximately $554,000.

Several other institutional investors also recently bought and sold shares of the company. QS Investors LLC grew its stake in shares of MEDNAX by 0.3% during the second quarter. QS Investors LLC now owns 3,812 shares of the company’s stock worth $230,000 after purchasing an additional 12 shares in the last quarter. Pacer Advisors Inc. grew its stake in shares of MEDNAX by 8.1% during the second quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock worth $117,000 after purchasing an additional 145 shares in the last quarter. Commonwealth Bank of Australia grew its stake in shares of MEDNAX by 15.3% during the second quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock worth $132,000 after purchasing an additional 293 shares in the last quarter. Thrivent Financial For Lutherans grew its stake in shares of MEDNAX by 5.5% during the second quarter. Thrivent Financial For Lutherans now owns 18,730 shares of the company’s stock worth $1,131,000 after purchasing an additional 970 shares in the last quarter. Finally, Prudential Financial Inc. grew its stake in shares of MEDNAX by 1.7% during the second quarter. Prudential Financial Inc. now owns 59,530 shares of the company’s stock worth $3,594,000 after purchasing an additional 1,010 shares in the last quarter. 98.43% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Cesar L. Alvarez sold 10,668 shares of the stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $42.59, for a total transaction of $454,350.12. Following the completion of the sale, the director now owns 44,215 shares in the company, valued at $1,883,116.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider John C. Pepia sold 3,000 shares of the stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the sale, the insider now owns 35,569 shares of the company’s stock, valued at approximately $1,834,649.02. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by corporate insiders.

A number of brokerages recently commented on MD. Citigroup lowered their target price on shares of MEDNAX from $52.00 to $47.00 and set a “neutral” rating for the company in a research note on Friday, November 3rd. Jefferies Group restated a “hold” rating and issued a $44.00 price objective on shares of MEDNAX in a research note on Friday, November 3rd. Robert W. Baird upped their price objective on shares of MEDNAX from $47.00 to $48.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd. KeyCorp upgraded shares of MEDNAX from a “sector weight” rating to an “overweight” rating and set a $51.00 price objective for the company in a research note on Sunday, September 17th. Finally, Zacks Investment Research upgraded shares of MEDNAX from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $53.82.

MEDNAX Inc (MD) opened at $53.44 on Tuesday. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.62. MEDNAX Inc has a 12 month low of $40.56 and a 12 month high of $72.13. The stock has a market cap of $5,004.94, a price-to-earnings ratio of 18.88, a price-to-earnings-growth ratio of 1.72 and a beta of 0.39.

MEDNAX (NYSE:MD) last released its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.87. MEDNAX had a net margin of 7.76% and a return on equity of 10.80%. The company had revenue of $868.95 million during the quarter, compared to the consensus estimate of $864.78 million. During the same quarter in the prior year, the firm posted $1.09 earnings per share. MEDNAX’s revenue for the quarter was up 4.9% on a year-over-year basis. equities research analysts forecast that MEDNAX Inc will post 3.1 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2018/01/02/gsa-capital-partners-llp-takes-position-in-mednax-inc-md.html.

About MEDNAX

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.